key: cord-1015727-os75no4m
authors: Broderick, Patricia A.; Phelan, Frank T.; Eng, Frank; Wechsler, Robert T.
title: Ibogaine modulates cocaine responses which are altered due to environmental habituation: In vivo microvoltammetric and behavioral studies
date: 1994-11-30
journal: Pharmacology Biochemistry and Behavior
DOI: 10.1016/0091-3057(94)90092-2
sha: 253af824466307bf9415fd7419f6029dc9180939
doc_id: 1015727
cord_uid: os75no4m

Abstract Ibogaine, a serotonergic (5-HTergic) indole alkaloid, was studied for cocaine modulatory effects on four parameters of behavior by computerized infrared photocell beam detection. The behavioral parameters were: a) locomotor activity (ambulations), b) rearing, c) stereotypy (fine movements, primarily grooming), and d) agoraphobia [(thigmotaxis) a natural tendency to avoid the center of the behavioral chamber]. With each behavioral data point, dopamine (DA) release, and serotonin (5-HT) release were detected within seconds in nucleus accumbens (NAcc) of the same behaving male Sprague-Dawley rats, using in vivo electrochemistry (voltammetry). Ibogaine was administered (40 mg/kg IP) for 4 consecutive days. Importantly, the DAergic and the 5-HTergic responses to (SC) cocaine and two behavioral responses, ambulations and central ambulations, were reduced in intensity due to extended time spent in the novel behavioral chamber (habituated). Rearing and fine movement patterns were not habituated. The results show that ibogaine downmodulated the (SC) cocaine-induced increase in NAcc DA release (p < 0.0001) and potentiated the (SC) cocaine-induced decrease in NAcc 5-HT release (p < 0.0001). Concurrently, ibogaine downmodulated cocaine-induced ambulation (p < 0.0001) and central ambulation behavior (p < 0.0001). On the other hand, the behavioral parameters that did not exhibit habituation, i.e., rearing behavior and fine movement behavior, were not downmodulated by ibogaine (p < 0.1558) (p < 0.3763), respectively. Furthermore, ibogaine itself did not significantly alter NAcc DA release over the 2-h period studied (p < 0.9113) although individual time points were significantly affected bidirectionally. Concurrently ibogaine significantly increased 5-HT release (p < 0.0155). Behaviorally, ibogaine appears to be a weak psychostimulant. The data show a critical modulatory role for 5-HT in ibogaine-cocaine interactions. Also elucidated as critical is the efficacy of ibogaine when the response to (SC) cocaine is decreased due to the habituation of the animals to their environment.

Cocaine Psychostimulant behavior Nucleus accumbens (NAcc) Dopamine (DA) Serotonin In vivo electrochemistry (Voltammetry) Stearate microelectrode Freely moving rat paradigm Locomotor activity Central locomotor activity (agoraphobic inhibition) Rearing behavior Stereotypy IBOGAINE, as a putative treatment for cocaine addiction, has a rather unique secular and historical perspective. Ibogaine has been purported to end the craving process for psy-chostimulants, such as cocaine, and for narcotics, such as heroin; the anecdotal reports have been given substance by the issuance of a use patent by the U.S. Office of Patents and i These results were originally presented at the Second Annual International Behavioral Neuroscience Society Conference held in Clearwater Beach, FL, April 22-25, 1993 .

2 Requests for reprints should be addressed to Dr. P. A. Broderick Trademarks (39) . Presently, Phase l clinical trials to determine the safety and pharmacokinetics of ibogaine (HC1) are progressing (44) and the National Institute on Drug Abuse (NIDA) is reported to be actively supporting studies to ascertain the clinical importance of ibogaine (67) . Ibogaine also has a rather unique scientific and historical perspective as well, in its pharmacognosy, chemistry, and in its pharmacology. The pharmacognosy of ibogaine describes the plant as the yellowish root of the African shrub Tabernanthe iboga Baillon of the family Apocynaceae. The plant is cultivated in Gabon, Africa. Interestingly, either rarely known or emphasized, is the fact that the alkaloids of the genera Apocynaceae have found extensive use in modern medicine, an example of which is the Rauwolfia alkaloids, from which the well-known drug reserpine is derived. The chemistry of ibogaine places this compound as an indole alkaloid, similar in structure to the neurotransmitter, serotonin (5-HT). L-Tryptophan is the precursor for ibogaine, which places ibogaine in the same biochemical pathway as 5-HT. Ibogaine was first isolated in 1901 by Dybowski and Landrin [cited in (21) ]. The chemical structure of ibogaine is known; its molecular formula is (C20HE6N20) (23) . Brain concentrations of ibogaine can be determined by thin layer chromatography, and concentrations of ibogaine in blood and urine can be determined by ultraviolet spectrophotometric assay (22) . The structural formula of ibogaine, which was suggested by Taylor in 1957 (66) , has been confirmed by x-ray crystallography (1) . The structure of many of the other iboga alkaloids have been deduced from that of ibogaine (23) . Interestingly, the origin of the indole alkaloid structure per se is predicated on yohimbine, a well known c~2-adrenoreceptor antagonist, which is actually derived from/-tryptophan, phenylalanine, and formaldehyde by two Mannich condensations (65) . There are other structural types of alkaloids of Apocynaceae, e.g., the isomeric quinindolines and quinindoles, such as quinolinic acid, are representative of one of the other basic structural types.

The studies of the peripheral pharmacology of ibogaine to date have been mainly concerned with the cardiovascular system. Ibogaine was found to decrease blood pressure in anesthetized animals and to increase blood pressure in unanesthetized animals (27) . Ibogaine was found to produce bradycardia; the bradycardic effect was potentiated by both domperidone and sulpiride, D E receptor antagonists and by atropine, a muscarinic cholinergic antagonist (35) . There have been reports that tabernanthine, an ibogaine congener, is a calcium entry blocker that also affects cellular calcium metabolism by inhibiting norepinephrine (NE) and calcium (Ca2+)induced vascular contractions (34) . In other similar studies, tabernanthine was found to have a dose-dependent potentiation (low dose) and inhibition (high dose) of contractions elicited by NE in the mesenteric artery so that it has actions related to the turnover of intracellular Ca 2+ releasable by NE (45) . Peripherally, tabernanthine has been observed to potentiate Ca 2+ responses and produce a catecholamine sensitization in isolated rat duodenum (70) . Finally, ibogaine itself produces hypoglycemia (21) .

Studies on the central nervous system pharmacology of ibogaine have shown that ibogaine can produce tremors in mice (62, 75, 76) and in rats (63) . The nontremorigenic doses of ibogaine have been reported to be 5 and 10 mg/kg IP (61) . Cappendijk and Dzoljic (15) have reported that the tremorigenic dose of ibogaine is 80 mg/kg and a lower dose of 40 mg/kg produces less prominent and shorter-lasting behavioral effects than the higher dose. Although, it has been shown that ibogaine itself did not interact at either the benzodiazepine receptor or the closely related GABAA receptor (19) , the tremor induced by a related compound, tabernanthine, has been studied; tabernanthine acted as a benzodiazepine receptor inverse agonist in vitro in a discriminant binding assay. In addition, a tabernanthine-induced tremor was functionally inhibited by the benzodiazepine antagonist, RO-15,1788 (69) .

Further studies on the central nervous system pharmacology of ibogaine have shown that ibogaine increased arousability (57) . These results are consistent with data from sleep studies that show that the ibogaine congeners, tabernanthine tartrate and tabernanthine parachlorophenoxyacetate (SAD 103), provoked an increase in wakefulness level, a reduction in the level of slow wave sleep, and a transient blocking of paradoxical sleep (17, 18) . Both ibogaine and its congener tabernanthine produced an increase in the energy of the theta band frequency (5-6 Hz) and increased the duration of wakefulness in rats and the level of vigilance in the human. Indeed, ibogaine was reported to act like an antidepressant in these sleep paradigms (20, 33) . Studies on the hallucinatory effects of ibogaine in humans have been reported [(58) and cited by Dhahir, 1971 (21) ]. According to the latter citation (21) , Dr. Sigg has described his own experiences with ibogaine as the following: "visual hallucinations, blue disks appearing only in the dark, accompanied by many other symptoms common to hallucinogenic intoxication, but no undesirable after effects, [such as] exhaustion or depression were noted."

Controlled studies on the toxic effects of ibogaine began in 1971 (21) , where tissue distribution and excretion studies were done in rats. The findings showed that ibogaine (50 mg/kg IP) was located in high concentrations in the liver, kidneys, and brain. Concentrations of ibogaine, however, were not cumulative and ibogaine disappeared at a rate of 4% of the injected dose per hour. About 507o of the injected dose of ibogaine was excreted unchanged in urine. The tissue : blood ratio was high, suggesting that the blood may not be the specimen of choice for postmortem toxicological analysis. Further, toxicological studies using chronic doses of ibogaine showed that ibogaine (10 and 50 mg/kg IP) did not cause any significant pathologic changes in the liver, kidney, heart, and brain when ibogaine was administered for 30 consecutive days, and no pathologic changes were observed in the liver or kidneys after ibogaine (40 mg/kg) was administered for 12 consecutive days. By comparison, when 5-HT was administered in doses of 10 mg/kg (base) for 12 consecutive days, severe damage to the kidney characteristic of ischemic coagulation necrosis occurred (21) . More recent findings show that ibogaine at high doses (100 mg/kg IP) and administered chronically, activates glial ceils in distinct longitudinal zones of the cerebellum, and causes degeneration of Purkinje cells, the major neurons of the cerebellar cortex. Interestingly, prior destruction of the inferior olive blocked Purkinje cell destruction (47, 48) . However, in many other brain areas, O'Hearn and Molliver found no evidence of ibogaine toxicity [citation in (67) ].

Insofar as ibogaine and the pharmacology of addiction is concerned, studies on the ability of ibogaine to block cocaine self-administration were positive in male rats (15) . In addition, the ability of ibogaine to block morphine self-administration was also positive, but in some cases somewhat discrepant in female rats (29, 31) . Results show that the ability of ibogaine to alleviate opiate withdrawal are equivocal, some are positive, some are negative (24, 26, 30, 61) . Moreover, ibogaine at a very low dose (3.5-7.0 mg/kg) did not significantly affect cocaine discrimination (55) .

The ibogaine reports on the neurochemistry of DA and locomotor behavior are varied, probably as much as the pa-rameters and paradigms are varied. Ibogaine did not affect extracellular concentrations of DA in NAcc of male rats as monitored by the microdialysis technique (41) . Importantly, in postmortem studies though, ibogaine decreased DA levels in female rats (43) . Moreover, ibogaine increased cocaineinduced and amphetamine-induced extracellular concentrations of DA in NAcc in female rats (40, 42) , whereas ibogaine decreased the usually increased extracellular concentrations of DA after morphine administration in male rats (41) . In mice, ibogaine reduced amphetamine (59) and cocaine-induced locomotor stimulations (60) .

Very few studies have been done on the interaction between ibogaine and the neurochemistry of the neurotransmitter serotonin (5-HT) except for early studies focussed on hypoxia (46) . Importantly, ibogaine produces side-to-side head weave (63), a classical 5-HTergic syndrome (68) .

We have published a series of articles that show that cocaine acts on presynaptic release mechanisms to alter synaptic concentrations of DA and 5-HT in a colocalized fashion in A~0 pathways (7) (8) (9) (10) (11) 13) . Our light microscopic immunocytochemical evidence for 5-HT in A~0 nerve terminals shows that the core of NAcc contains a dense terminal field of tyrosine hydroxylase (TH) axons that have an extensive overlap with 5-HT axons in the periphery within the core (51, 52) . Importantly, we have studied the region of NAcc that is ventral and lateral to the anterior commissure. This region has been referred to as ventrolateral NAcc (vlNAcc) by Swanson and Cowan (64) ; it has been suggested by these authors that vlNAcc has reciprocal connections with ventrai tegmental area (VTA). Our findings of 5-HT axons in close proximity to DA neurons in vlNAcc are consistent with ultrastructural studies that show 5-HT immunoreactive terminals in the core and shell of medial NAcc (72) and with very recent studies that show a prominence of asymmetric junctions formed by 5-HTlabeled terminals on neurons projecting to the NAcc with those containing tyrosine hydroxylase in the VTA (71) .

Therefore, the purpose of the present study was to assess the effect of ibogaine both alone and on cocaine-induced alterations in DA and 5-HT release in vlNAcc of freely moving and behaving male rats, concurrently with a study of the effect of ibogaine on locomotor activity and other parameters of cocaine-induced psychostimulant behaviors. Changes in synaptic concentrations of DA and 5-HT reflect presynaptic release mechanisms because in vivo microvoltammetric studies using 3,BL, have shown that cocaine does not increase DA concentrations in the presence of an impulse flow blocker (8) . The results of the in vivo microvoltammetric studies are consistent with earlier studies that have described the dopamine releasing properties of cocaine (56) . The well-known action of cocaine on reuptake inhibition processes (53, 54) are not precluded.

A paradigm of altered responses to cocaine due to extended habituation of the animal in a novel environment was chosen. This paradigm more closely mimics clinical conditions.

Ibogaine (40 mg/kg IP) was administered in suspension, each consecutive day for 4 days before the in vivo voltammetric and behavioral studies were performed. Ibogaine (Sigma, St. Louis, MO) was suspended in doubly deionized water and stirred for at least 40-50 min on a Thermolyne stirring plate. On each experimental day (the fourth day of ibogaine injection), after stable in vivo electrochemical signals for DA and 5-HT were evident, ibogaine (40 mg/kg IP) was administered and studied for 2 h after exploratory behavior was completed and baseline neurotransmitter release was stabilized. Then, 2 h after the administration of ibogaine, cocaine HC1 (Sigma) (20 mg/kg SC), dissolved in doubly deionized water, was injected and the effects of cocaine (20 mg/kg SC) were studied for 4h.

In another group of male Sprague-Dawley rats, physiological saline (1 cc/kg IP) was administered instead of ibogaine; the (SC) cocaine protocol and the neurochemical and behavioral protocols remained the same. The results were then compared with the effect of (SC) cocaine on DA and 5-HT release in vlNAcc in freely moving and behaving rats when cocaine (SC) injection was not preceded by a 2-h saline study (7) . It is important to note that in the latter study, animals had completed exploratory behavior in their novel environment before cocaine injection.

In the present studies, animals were allowed a 2-h extended time period in the novel behavioral chamber before either injection of cocaine (20 mg/kg SC) or injection of saline (bodyweight in kg IP) was given. Due to the resulting extended habituation of the animal in the novel behavioral chamber, the DAergic responses, the 5-HTergic responses, and the behavioral responses to (SC) cocaine of hyperactivity and antiagoraphobia were significantly changed. Therefore, ibogaine was studied for its effects on (SC) cocaine responses, which were environmentally habituated. Also, results on rearing behavior and stereotypic behavior after cocaine injection that were not affected by environmental habituation, are reported.

The studies were done in unrestrained, freely moving, male, virus-free Sprague-Dawley rats (Charles River, Kingston, NY) (weight range 327 to 394 g at the time of the in vivo electrochemical and behavioral studies). The animals were fed Purina Rat Chow and water ad lib and were group housed before surgery and individually housed after surgery. A 12 h dark/light cycle was maintained both during the housing of the laboratory rats and throughout the experimental studies. The rats were tested free from the following viruses: Sendai 

Male Sprague-Dawley rats were anesthetized with pentobarbital (Na) (50 mg/kg IP). Body temperature was continuously maintained at 37 _+ 0.5°C with an aquamatic K module heating pad (Amer. Hosp. Supply, Edison, N J). Booster shots of pentobarbital (Na) (0.05 cc) were administered to maintain adequate anesthesia. Corneal, pinnal, and leg flexion responses were absent throughout the surgery. Rats were stereotaxically implanted with stearate working microelectrodes in ventrolateral (vl) NAcc (AP = +2.6, ML = +2.5, DV = -7.3) (50), which is the ventrolateral region of the posterior part of NAcc, as has been previously described (Swanson and Cowen (64) ). Ag/AgCl reference microelectrodes and stainless steel auxiliary microelectrodes were placed in contact with cortex. The working, reference, and auxiliary microelectrode assembly was held in place with dental acrylic (Kadon Cavity Liner, Caulk, Becker Parkin Dental Supply Co. Inc., NY). 714 BRODERICK ET AL.

The stearate microelectrode paste mixture consisted of U.S.P. ultra superior purity carbon (1.5 g) (Ultra-Carbon Corp., Bay City, MI) extra heavy Nujol (1.24 cc) (Plough, Memphis, TN), and 9907o stearic acid (100 mg) (Sigma, St. Louis, MO). The stearate microelectrode was fabricated by pulling the Teflon envelope surrounding the stainless steel wire (Medwire Corp., Mt. Vernon, NY) over the edge to form a microcavity inside the Teflon well. The length of the resulting Teflon well was 500 #m; the diameter of the Teflon well was 200 ~tm. The detailed methodology for both the microelectrode assembly and the synthesis of the paste mixture is published by this laboratory (4) (5) (6) . The microelectrode specifications are different from those published by others (2, 3) . Also importantly, electrochemical (EC) macroelectrodes have different surface EC properties than microelectrodes and, thus, such EC phenomenon as catalysis cannot be directly compared (73) .

Dopamine and 5-HT were detected with the stearate microelectrode at peak potentials of +0.14 + 0.015 V and +0.29 _+ 0.015 V, respectively. Dopamine and 5-HT were detected within 10-15 s and 10-12 s, respectively, and appear sequentially in two separate waveforms on both in vivo and in vitro voltammograms. Dopamine was the first signal and 5-HT was the second signal to be detected in the time course of the applied potential (Eapp). Figure 1 shows a voltammogram of sequentially detected DA and 5-HT release in vlNAcc of freely moving and behaving Sprague-Dawley rats. Even at high concentrations, the anionic metabolite of DA, i.e., 3,4 dihydroxyphenylacetic acid (DOPAC), cannot be detected. At high concentrations ascorbic acid (AA), the cofactor in the DA biosynthetic pathway, can be detected. However, AA can be detected at 0.050 V, a different peak potential (E~p) than that for DA or 5-HT. The neurotransmitter, 5-HT was detected < t_ t_. within a 10-12 s time period, at an Eao of +0.290 V + 0.015 V. The metabolite of 5-HT, that is, 5-hydroxyindoleacetic acid (5-HIAA) cannot be detected. Uric acid (UA), which is a constituent of brain with similar electroactive Eap properties to those of 5-HT, can be detected but not at the same peak potential as that for 5-HT. Increasing the concentrations of DA and 5-HT did not significantly affect either signal. Each voltammogram was completed within 60 s. Each voltammogram, consisting of detection of faradaic in vivo electrochemical signals for DA and 5-HT, was completed in 25 s. A calibration curve for the detection of DA and 5-HT with the stearate (1.24 cc Nujol) microelectrode is previously published by this laboratory (11) . Medium exchange technique for stearate microelectrodes. A medium exchange technique was performed on each microelectrode in vitro before surgical insertion and implantation of the microelectrode in vivo. This procedure consisted of performing a selective preconcentration of the analytes DA and 5-HT onto the microelectrode surface in saline phosphate buffer (0.01 M) pH 7.4 in a closed semidifferential circuit scanning from -0.2 V to +0.4 V at 2 nA/V for three to five exposures with a 2-min cell deposition. This method achieves optimum and stable preconcentration of analytes and improves the selectivity, the efficacy, and the sensitivity of the microelectrode for analytes in an electrolyte environment.

In vivo voltammetric (semiderivative) studies on conscious rats were begun approximately 9-14 days after the aseptic surgical procedures were performed. On each experimental day, an animal was placed in a Faradaic and Plexiglas chamber (dimensions: 24 x 18 x 23.5"). The three microelectrode assembly, enclosed within the animal's prosthetic acrylic cap, was connected to a CV37 detector (BAS, West Lafayette, IN) by means of a mercury commutator (Br. Res. Instr., Princeton, N J), a flexible cable, and a mating connector (BJM Electronics, Staten Island, NY). The CV37 was electrically connected to a Minigard surge suppressor (Jefferson Electric, Magnetek, NY), which was then connected to an isolated electrical ground. Potentials were applied to the working microelectrode with respect to a Ag/AgC1 microelectrode (0.16 M saline) by a CV37 detector-potentiostat. There was a 6-rain interval between the completion of one voltammogram and the 2-min cell activation for the next voltammogram. Nonfaradaic charging current was eliminated in the first 20 s of each scan. Initial applied potential (E 0 was -0.200 V. The scan rate was 10 mV sec i.

Activity pattern analysis simultaneously monitored several different responses both as they occurred spatially and temporally. The APM measured multiple concurrent measures of ambulations (locomotor activity), central ambulations, rearing behavior, and fine movements (primarily grooming). The movement of each male Sprague-Dawley rat was detected by a 16 x 16 array of infrared photobeams that surrounded the behavioral chamber; the photobeams were held in place by an aluminum frame. The aluminum frame was placed 3/4 inch above the Plexiglas floor of the behavioral cage (24 x 18 x 23.5"). The infrared photobeams were sampled by an IBM computer that defined the x-y position of the animal within a 1.5 inch resolution. An outer exterior layer of the behavioral chamber consisted of copper that provided a faradaic shield for the in vivo monitoring of electrochemical (voltammetric) signals.

The definition of the specific x-y position of the animal was important because when an x-y position was calculated, it was used to define an animal's position in one of 16 equally sized sectors and one of 9 unequally sized regions. These regions were then used for more descriptive measures of, e.g., entries spent in the center of the cage. This central entries parameter of locomotor behavior becomes a reliable measure of thigmotaxia, i.e., the agoraphobic response, which is considered to be equivalent to fear (28) . Moreover, rearing, wherein both forepaws of the animal are away from the floor for a period of at least 1 s, was measured by another series of infrared photobeams situated about 6 inches from the floor of the behavioral chamber. An IBM computer sampled the status of all the beams and the circuits in the behavioral chamber every 100 ms. The system is a custom modified version of an Activity Pattern Monitor (APM) (San Diego Instruments, San Diego, CA). Each parameter of behavior was monitored concurrently with the online detection of DA release and the separate yet concurrent detection of 5-HT release.

Each component of the behavior monitored online, in addition to the DA and 5-HT release detected on line, was tested for statistically significant differences between pre-and postibogaine-cocaine and pre-and postsaline-cocaine, by analysis of variance (ANOVA) (Statview, Brain Power Inc., Calabasas, CA). Moreover, differences between ibogaine and control and saline and control were also determined by ANOVA. ANOVAs were followed by post hoc tests, Fisher PLSD (least square differences), and the Scheffe F-test (Statview, Brain Power Inc., Calabasas, CA), to determine hourly statistically significant differences. The hourly data was a composite of the individual 10-min interval time course data points. Statistically significant differences were also calculated on the individual time course data points by 95°70 confidence limits (95070 CL), setting the p-value at p < 0.05. Changes in DA and 5-HT values after drug or saline vis-A-vis untreated (same animal) controls are presented as percent change, whereas behavioral data are presented as frequency or number of behavioral events. Control is represented as 100070.

Because the actual detection time for DA was 10-15 s, the percent change in synaptic concentrations of DA at each data point represents a 10-15 s current change (pA) from baseline. A similar principle of in vivo electrochemical detection applies for 5-HT. Because the actual detection time for 5-HT at each data point is 10-12 s, the percent change in synaptic concentrations of 5-HT, at each data point, represents a measurement of electrical current (in pA) within the same discrete synaptic environment as that for DA, within vlNAcc within a 10-12 s time period.

Finally, basal (endogenous) saline and cocaine-altered DA and 5-HT release in vlNAcc and concurrent parameters of behaviors were studied for statistically significant correlative value by the Pearson Product Moment Coefficient of Correlation (r) (polynomial distribution) (Statview, Brain Power Inc., Calabasas, CA). Corresponding z values were derived from the table of z for values of r from 0.0 to 1.0.

Placement of working microelectrodes in vlNAcc was confirmed by the potassium ferrocyanide blue dot method (10070 formalin-transcardial perfusion with 80 ml saline). Current was passed at an amperage of 50 #A in a time period of 30 s. Examination of the brain revealed that virtually no damage to brain tissue took place. Figure 1 shows a semiderivative voltammogram of basal DA and 5-HT release, detected concurrently in vlNAcc. The peak potential for the in vivo electrochemical signal for DA was 0.140 +_ 0.015V and that for 5-HT was 0.290 +_ 0.015V. Lowest detection limits, currently possible for DA and 5-HT, are 5 nmol and 1 nmol, respectively. The hourly data was a composite of the individual 10-min interval time course data points. There were, however, small but statistically significant (p < 0.05 (95070 CL)) initial decreases in DA release followed by small but statistically significant increases in DA release, at specific time intervals during the time course studies. DA release at the time points (20, 40 , and 50 min) following ibogaine injection were significantly decreased below basal DA release (95070 CL) and DA release at time points (60, 80, 90, and 100 min) following ibogaine injection were significantly increased over basal DA release (95070 CL). The temporal resolution of in vivo electrochemistry allowed the selective effects of ibogaine on DA release to be detected.

(b) Phase 2: Effect of (SC) cocaine with ibogaine pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h ibogaine study, produced a significant increase in DA release in vlNAcc over baseline [ANOVA: F(4, 25) = 41.619, p < 0.0001]. DA release was significantly increased to 106070 at 130 min (p < 0.05, 95070 CL) and maximally increased to 122°/0 (p < 0.05, 95070 CL) at 320 min (baseline = 100070). Post hoc analyses show that the statistically significant differences between basal and cocaine-induced DA release were significant for each of the 4 h following cocaine injection (Fisher's PLSD = 3.659 and Scheffe's F = 3.183, 12.755, 23.225, 31.485, first to fourth hours, respectively). It is important to note that saline or ibogaine injections were administered chronically for 4 days. The day of the study was the fourth day of saline or ibogaine injection. ",, 7]). In vivo electrochemical signals for DA and 5-HT were detected concurrently. Both the saline group and the ibogaine group each had injections of either saline or ibogalne respectively for 3 consecutive days before the day of and on the day of the study. *p < 0.05; 9507o confidence limits (CL). See text for ANOVA statistics. mine and 5-HT release were studied concurrently with a temporal resolution of 10-15 s and 10-12 s, respectively. In vivo electrochemical signals for DA and 5-HT peaks were separate, distinct and on-line. (b) Phase 2: Effect of (SC) cocaine with saline pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h saline study caused a significant decrease in 5-HT release below baseline [ANOVA: F(4, 25)= 26.544, p < 0.0001]. 5-HT release was significantly decreased beginning at 170 min to 10070 below baseline (p < 0.05, 95070 CL) and maximally decreased to 30070 below baseline (p < 0.05, 95070 CL) at 300 min (baseline = 10007o). Post hoc analyses show that the statistically significant differences between basal and cocainealtered release of 5-HT were significant for each of the 4 h following cocaine (20 mg/kg SC) injection (Fisher's PLSD = 5.85 and Scheffe's F = 1.236, 9.71, 13.556, 18.71, first to fourth hours, respectively). 

n i * i, it, i, i,i, i,

A comparison between the effect of saline and the effect of ibogaine on 5-HT release shows that ibogaine significantly increased 5-HT release over saline in the first hour following baseline [ANOVA: F(I, 5) = 7.96, p < 0.0371, ANOVA: F(I, 5) = 5.82, p < 0.0607, first and second hours, respectively, following baseline).

A comparison between the effect of cocaine on 5-HT release with saline pretreatment vs. ibogaine pretreatment shows that ibogaine significantly potentiated the cocaine-induced decrease in 5 

Post-Cocaine Time in Minutes   FIG. 4 . DA and 5-HT release in vlNAcc: Effect of (SC) cocaine without saline or ibogaine pretreatment: animals not habituated (not extended habituation) to novel environment: time period not extended. The effect of cocaine (20 mg/kg SC) on synaptic concentrations of DA and 5-HT in vlNAcc when cocaine was injected without an immediately preceding 2-h study of either saline or ibogaine. *p < 0.05; 95% confidence limits (CL). See text for ANOVA statistics (N = 5). Modified from Broderick (7) . Reprinted with permission of Elsevier Science, Ltd.

significantly decreased beginning at 20 min to 11070 below baseline (p < 0.05, 95o70 CL) and maximally decreased to 37°7o below baseline (p < 0.05, 95°70 CL) at 190 min (baseline = 100%).

A statistical comparison between the effect of cocaine on DA release with repeated environmental stimulation (extended time period in novel behavioral chamber) and that effect without, shows that the repeated stimulation response to (SC) cocaine was significantly reduced [ANOVA: F(I, 23) = 9.994, p < 0.0044]. Therefore, cocaine-induced DA release was significantly habituated and downmodulated by the number of hours the animal spent in the behavioral chamber, even in a novel behavioral chamber. Importantly, the most prominent habituation effects on DA release were seen in the second hour (b) Phase 2: Effect of (SC) cocaine with ibogaine pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h ibogaine study caused a significant increase in cocaine-induced ambulation frequency over baseline [ANOVA: F(4, 25) = 28.812, p < 0.0001]. Ambulation frequency was significantly increased from 118 ambulations at baseline to 583 ambula-tions (p < 0.05, 95°7o CL), beginning at 130 min. Ambulation frequency was maximally increased to 1090 ambulations (p < 0.05, 95% CL) at 300 min. Post hoc analyses show that the statistically significant differences between basal and cocaineinduced ambulation frequency were significant for each of the 4 h following cocaine injection (Fisher's PLSD = 153.305 and Scheffe's F = 5.309, 10.666, 17.35, 23.785, first to fourth hours, respectively).

A comparison between the effect of saline and the effect of ibogaine on ambulation frequency shows that ibogaine significantly increased ambulation frequency in the second hour following baseline [ANOVA: F(1, 5) = 0.084, p < 0.7836, ANOVA: F(I, 5) = 46.82,p < 0.001, first and second hours, respectively, following baseline).

A comparison between the effect of cocaine with saline pretreatment vs. the effect of cocaine with ibogaine pretreatment shows that ibogaine significantly reduced cocaine- Figure 6 shows the effect of cocaine on ambulation behavior when cocaine (20 mg/kg SC) was injected without an immediately preceding 2-h study of either saline or ibogaine. Cocaine (20 mg/kg SC) significantly increased ambulation frequency [ANOVA: F(4, 25) = 58.845, p < 0.0001]. Ambulation frequency was significantly increased from a baseline of 253 ambulations to 707.25 ambulations, beginning at the 10min mark (p < 0.05, 95% CL). Ambulation frequency was maximally increased to 1578 ambulations (p < 0.05, 95% CL) at the 210-min mark.

A statistical comparison between the effect of cocaine on ambulation frequency with repeated environmental stimulation and that without shows that the repeated stimulation response to (SC) cocaine was significantly reduced [ANOVA: F(I, 23) = 14.994, p < 0.0008]. Therefore, a subsequent habituated and downmodulated response to (SC) cocaine was seen with the ambulatory behavior parameter, particularly in the first [ANOVA: F(I, 5)= 19.873, p < 0.0067], and fourth hours [ANOVA: F(1, 5) = 13.972, p < 0.0135]. Figure 7 shows the effect of saline (1 cc/kg IP) on rearing behavior, in addition to showing the effect of cocaine (20 mg/ kg SC) on rearing behavior which follows the 2-h saline study. The study was done in the same freely moving and behaving male Sprague-Dawley rats in which vlNAcc DA release and 5-HT release and ambulatory behavior were studied, i.e., the saline-cocaine group. 

FIG. 6. Frequency of ambulatory behavior: effect of (SC) cocaine without saline or ibogaine pretreatment: animal group not habituated (not extended habituation) to novel environment: time period not extended. The effect of cocaine (20 mg/kg SC) on ambulatory behavior when cocaine was administered without a 2-h saline or ibogaine study preceding cocaine injection, vlNAcc DA and 5-HT release was studied concurrently (Fig. 4) . Ambulatory (locomotor) behavior is reported in terms of frequency (number) of events. *p < 0.05; 95% confidence limits (CL). See text for ANOVA statistics (N = 6). (b) Phase 2: Effect of (SC) cocaine with saline pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h saline study significantly increased rearing frequency over baseline [ANOVA: F(4, 25) = 22.852, p < 0.0001]. Rearing frequency was significantly increased from 2 rears at baseline to 12 rears (p < 0.05, 95070 CL), beginning at 190 min, and was maximally increased to 58 rears (p < 0.05, 95o70 CL) at 300 min. Post hoc analyses show that the statistically significant differences between basal and cocaine-induced rearing frequency were significant for the second to fourth hours following cocaine (20 mg/kg SC) injection (Fisher's PLSD = 11.63 and Scheffe's F = 5.557, 12.13, 13.341, second to fourth hours, respectively). (b) Phase 2: Effect of (SC) cocaine with ibogaine pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h ibogaine study significantly increased rearing frequency over baseline [ANOVA: F(4, 25) = 31.036, p < 0.0001]. Rearing frequency was significantly increased from 1 rear at baseline to 16 rears (p < 0.05, 95°70 CL), beginning at 130 min. Rearing behavior was maximally increased to 51 rears (p < 0.05, 95% CL) at 310 rain. Post hoc analyses show that the statistically significant differences between basal and cocaineinduced rearing frequency were significant for each of the 4 h following cocaine injection (Fisher's PLSD = 8.213 and Scheffe's F = 2.418, 8.808, 10.198, 27 .871, first to fourth hours, respectively).

A comparison between the effect of saline and the effect of ibogaine on rearing behavior shows that there were no significant differences in rearing frequency for either hour of the 2 h following baseline [ANOVA: F(1, 5) = 0.179, p < 0.6899, ANOVA: F(1, 5) = 4.533, p < 0.0865, first and second hours, respectively, following baseline].

A comparison between the rearing effects of cocaine with saline pretreatment vs. ibogaine pretreatment shows that there was no significant difference between saline and ibogaine on cocaine's effect on rearing frequency [ANOVA: F(1, 23) = 2.154, p < 0.1558] over the 4 h following cocaine injection. Figure 8 shows the effect of cocaine on rearing behavior when cocaine (20 mg/kg SC) was injected without the immediately preceding studies (2 h) of either saline or ibogaine. Cocaine significantly increased rearing frequency over baseline [ANOVA: F(4, 25) = 48.371, p < 0.0001]. Rearing frequency was significantly increased from a baseline of 4 rears to 16 rears beginning at 10 min (p < 0.05, 95% CL). Rearing behavior was maximally increased to 49 rears (p < 0.05, 95°7o CL) at 100 min.

A statistical comparison between the rearing effects of cocaine when studied with repeated environmental stimulation and that without, shows that there was no significant difference between the two [ANOVA: F(1, 23) = 0.236, p < 0.6318]. Therefore, the psychostimulant rearing behavior induced by cocaine did not exhibit the habituated response to cocaine that was seen with both neurochemical responses to cocaine and the behavioral ambulatory response to (SC) cocaine. Therefore, ibogaine did not downmodulate cocaineinduced rearing behavior a response that was not habituated. Figure 9 shows the effect of saline (1 cc/kg IP) on frequency of stereotypy (fine movement behavior), in addition to showing the effects of cocaine (20 mg/kg SC) on fine movement behavior which follow a 2-h saline study. The study was done in the same freely moving and behaving male Sprague-Dawley rats in which vlNAcc DA and 5-HT release were concurrently detected as well as the same animals in which the psychostimulant cocaine-induced behaviors of ambulations and rearing behavior were concurrently monitored. caine-induced fine movement frequency was significant for the second to fourth hours following cocaine injection (Fisher's PLSD = 15.264 and Scheffe's F = 11.405, 15.123, 13.673, second to fourth hours, respectively). Figure 9 also shows the time course effects of ibogaine (40 mg/kg IP) on fine movement frequency, in addition to showing the effect of cocaine (20 mg/kg SC) on fine movement frequency which follows the 2-h ibogaine study. The study was done in the same freely moving and behaving male Sprague-Dawley rats in which vlNAcc DA and 5-HT release, ambulatory, and rearing behavior were studied concurrently (ibogaine-cocaine group).

(a) Phase 1: Effect of (SC) ibogaine. Ibogaine significantly increased fine movement frequency for the first hour of the 2 h following baseline [ANOVA: F(1, 10) = 5.637,p < 0.039]. Ibogaine significantly increased fine movement frequency at the 10 and 70 min marks (p < 0.05, 95070 CL). Ibogaine had a similar effect to saline within the first 10 min due to arousal of the animal since exploratory behavior was completed and rest had ensued.

(b) Phase 2: Effect of (SC) cocaine with ibogaine pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h ibogaine study produced a significantly increased fine movement frequency over baseline [ANOVA: F(4, 25) = 25.6762, p < 0.0001]. Fine movement frequency was significantly increased from 9 fine movements at baseline to 24 fine movements (p < 0.05, 95070 CL), beginning at 130 min. Fine movements were maximally increased to 80 fine movements (p < 0.05, 95°70 CL) at 300 rain. Post hoc analyses show that the statistically significant differences between basal and cocaineinduced fine movement frequency were significant for each of the 4 h following cocaine injection (Fisher's PLSD = 12.425 and Scheffe's F = 1.748, 6.19, 9.313, 22 .545, first to fourth hours, respectively).

A comparison between the effect of saline and the effect of ibogaine on fine movement frequency shows that ibogaine significantly increased fine movement frequency over saline in the second hour [ANOVA: F(I, 5) = 3.095, p < 0.1389, ANOVA: F(I, 5) = 8.004, p < 0.0367, first and second hours, respectively).

However, a comparison between the effect of cocaine with saline pretreatment vs. ibogaine pretreatment, shows that there was no significant difference between saline and ibogaine on cocaine-induced fine movement behavior [ANOVA" F(1, 23) = 0.814, p < 0.3763] over the 4 h following cocaine injection. However, ibogaine significantly increased cocaine's (20 mg/kg SC) effect on fine movement frequency by 12 fine movements in the first hour [ANOVA: F(1, 5) = 17.403, p < 0.0087]. Figure 10 shows the effect of cocaine on fine movement behavior when cocaine (20 mg/kg SC) was injected without an immediately preceding 2 h study of either saline or ibogaine. 

FIG. 10. Fine movement behavior: effect of (SC) cocaine without saline or ibogaine pretreatment: animals not habituated (not extended habituation) to novel environment: time period not extended. The effect of cocaine (20 mg/kg SC) on fine movement behavior when cocaine was administered without an immediately preceding 2-h saline or ibogaine study, vlNAcc DA and 5-HT release and ambulatory behavior were studied concurrently (Figs. 4, 6, and 8 ). *p < 0.05; 95°7o confidence limits (CL). See text for ANOVA statistics (N = 6). 0.225, p < 0.6418]. The hourly data was a composite of the individual 10-min interval time course data points. Saline had an effect within the first 10 min due to arousal of the animal since exploratory behavior was completed and rest had ensued.

(b) Phase 2: Effect of (SC) cocaine with saline pretreatment. Injection of cocaine (20 mg/kg SC) following the 2-h saline study significantly increased central ambulation frequency over baseline [ANOVA: F(4, 25) = 38.867, p < 0.0001]. Central ambulation frequency was significantly increased from 0 central ambulations at baseline to 7 (p < 0.05, 95°7o CL), beginning at 170 min. Central ambulatory activity was maximally increased to 28 central ambulations (p < 0.05, 95% CL) at 330 rain. Post hoc analyses show that the statistically significant differences between basal and cocaineinduced central ambulation frequency were significant for the second to fourth hours following cocaine (20 mg/kg SC) injection (Fisher's PLSD = 4.618 and Scheffe's F = 12.844, 22.079, 19.373, second to fourth hours, respectively). 

A statistical comparison between the stereotypic effects of cocaine when studied with repeated environmental stimulation and that without, show that there were no significant differences [ANOVA: F(1, 23) = 1.791, p < 0.1939] over the 4 h following cocaine injection. Therefore, the cocaine-induced fine movement response does not exhibit habituation. The effect is similar to rearing. Thus, ibogaine did not downmodulate the cocaine-induced stereotypic behavioral response, a response that was not habituated. (11) or ibogaine (tO) on central ambulations (agoraphobia inhibitions) (N = 4, 5, respectively), vlNAcc DA and 5-HT release, ambulations, rearing behavior, fine movements, and central ambulations were concurrently monitored (Figs. 2, 3 , 5, 7, and 9). Phase 2: all parameters are exactly the same as described in Figs. 2, 3, 5, 7, and 9 because cocaine-induced effects on DA and 5-HT release and all parameters were concurrently monitored. *p < 0.05; 95% confidence limits (CL). See text for ANOVA statistics. tory, rearing, and fine movement behaviors were studied concurrently. Figure 12 shows the effect of cocaine on central ambulation behavior when cocaine (20 mg/kg SC) was injected without an immediately preceding study (2 h) of either saline or ibogaine. Cocaine significantly increased central ambulation frequency over baseline [ANOVA: F(4, 25) = 28.804, p < 0.0001]. Central ambulation frequency was significantly increased from a baseline of two central ambulations to four central ambulations beginning at the 10 min mark (p < 0.05, 95% CL). Central ambulations were maximally increased to 51 central ambulations (p < 0.05, 95% CL) at 220 min.

A statistical comparison between the effects of cocaine on central ambulatory behavior when studied with repeated environmental stimulation and that effect without, shows that the F(I, 5) = 118.848,p < 0.0001], first to fourth hours, respectively. Therefore, antiagoraphobic or antithigmotactic behavior, which is thought to represent or reflect an anxiolytic (anxiety-reducing) behavior, undergoes habituation such as that which was seen with the DA and 5-HT response and with the ambulatory response. Importantly, ibogaine downmodulated the habituated behavioral responses to (SC) cocaine, whereas the behavioral responses that were not diminished by habituation were not significantly affected by ibogaine. Figure 13 shows activity patterns for the habituated salinecocaine paradigm described in Figs. 5 and 11, i.e., when cocaine was administered after a 2-h saline study. Ambulatory and central ambulatory moments are shown. The initial stimulation caused by saline injection due to arousal is shown in the first hour postsaline pattern. The habituation response to cocaine is clear as compared with Fig. 14 which describes the nonhabituated response to (SC) cocaine, i.e., when no additional time is spent by the animal in the novel behavioral chamber. Figure 15 shows activity patterns for the habituated ibogaine-cocaine paradigm, i.e., when cocaine is administered after a 2-h ibogaine study. Ambulatory and central ambulatory moments are shown. Ibogaine itself appears to be a weak psychostimulant; the effects are ongoing in the second hour. A comparison of Figs. 13 and 15 shows that although cocaineinduced ambulations are reduced after ibogaine pretreatment, some activity remains which is clearly greater than that seen in the saline-cocaine group. Tables 1 and 2 show the highly significant correlative values between cocaine-induced 5-HT release in vlNAcc and cocaine-induced psychostimulant behaviors as well as the highly correlative values between cocaine-induced DA release and psychostimulant behaviors, both in the ibogaine-cocaine group (Table 1 ) and in the saline-cocaine group ( Table 2) .

New findings show that ibogaine significantly downmodulates the cocaine-induced increase in DA release in vlNAcc in the freely moving and behaving environmentally habituated rat model. The important distinction between the present studies and previous studies is that the present data are derived from a freely moving and behaving rat paradigm in which DA responses to (SC) cocaine have been diminished due to environmental habituation, i.e., each animal had a reduced responsiveness to DA release after (SC) cocaine, presumably due to the repeated environmental stimulation in the novel behavioral chamber. Moreover, this effect of (SC) cocaine on DA release on vlNAcc in an extended habituated environment was compared with previous studies in which the paradigm was completely the same with the one exception, that the protocol did not have an extended habituation component (7) . The response to cocaine in the habituated environment fits the classical definition of neurochemical habituation, i.e., that repeated action potentials in nerve terminals can accompany behavioral habituation by decreasing the number of open CA 2+ channels and inactivating synapses (36) .

These findings of the habituation aspects of ibogainecocaine interactions point to the necessity of a crucial assessment of the previous ibogaine-cocaine literature within the context of the varied experimental paradigms. Although there has been a recent surge of interest in preclinical research on the mechanism of action of ibogaine, there are only two previous papers specifically on ibogaine-cocaine DAergic interactions. One article is from the laboratory of Glick in the U.S. (40) , and the other is from the laboratory of Dzoljic in The Netherlands (15) . There are relevant differences in paradigms, i.e., a) Glick repetitive doses of ibogaine (40 mg/kg IP), and c) Glick's laboratory studied cocaine-induced extracellular concentrations of DA and locomotor behavior, whereas Dzoljic's laboratory studied the ability of ibogaine to affect the selfadministration of cocaine. The conclusions were consistent in that a potentiation of the cocaine-induced increase in extracellular concentrations of DA by ibogaine occurred (the ibogaine was administrated 19 h earlier) (40) , and there was a longlasting effect of ibogaine in its reported inhibition of cocaine self-administration (15) . Because DA antagonists classically increase the rate of cocaine self-administration (74), yet, given certain caveats, e.g., various rates of responding measures, the previous data may suggest that ibogaine does not act on cocaine self-administration through a direct DA receptor blockade. Consistent with the present findings is a previous study that reported that ibogaine per se did not significantly affect DA release in NAcc (41) . That ibogaine had no effects on extracellular concentrations of DA, as studied by dialysis, was again reported in 1992 by Maisonneuve and Glick (40) . It is important to note that postmortem HPLC-EC assays of ibogaine's effects on DA levels later showed that ibogaine decreased DA levels by 50070 1 h after ibogaine injection in NAcc, but 1 month later, DA was entirely unaffected by ibogaine (43) . Expectedly, the postmortem assay may have had additional variables as compared with results derived from in vivo microvoltammetry or dialysis studies. Nonetheless, the empirical data, to date, show that the general overall effects of ibogaine per se on NAcc DA release over time are not prominent.

Further support for ibogaine's inability to affect DA presynaptically in central nervous system is gleaned from reuptake studies, i.e., a) ibogaine at concentrations as high as 100 /~M did not significantly inhibit [3H] GBR-12935 binding to the DA transporter protein and 1 #M of ibogaine had no effect on in vitro striatal DA reuptake by a P2 membrane fraction (14) , b) in vivo treatment with ibogaine did not affect the binding of [3H] WIN 35, 248 to the cocaine binding site in striatal tissue measured in vitro (60) , and (c) ibogaine added, in vitro, had a weak affinity for the WIN 35,248 binding site (60) . Too, although the data, based on the action of ibogaine on DA receptors are incomplete, neither the D~ or the D 2 receptors in rat striatum and calf caudate, as studied by radioligands SCH 23390 and N-methyl spiperone respectively, were affected by ibogaine (19) . Thus, ibogaine may not act through DA receptors to downmodulate the cocaine induced increase in DA release in vlNAcc at the synapse. Ibogaine may act to downmodulate DA release at the synapse only under conditions of increased DA release and/or reuptake inhibition. Under the usual hypoxic conditions of increased DA release (12) , studies of ibogaine and DA function further support the latter hypothesis (16) . Thus, ibogaine's action on cocaine-induced DA release may well depend on the availability of DA at the synapse at least in an animal model of environmental habituation. Preliminary data from our laboratory show that ibogaine may not downmodulate DA release in vlNAcc after cocaine administration, when the animal has not undergone an extended habituation to its environment. An habituated environment may be a key to the underlying mechanism of action of cocaine on DA function.

New findings on the interaction of ibogaine and cocaine on 5-HT release in vlNAcc are reported here. Changes in 5-HT release in vlNAcc after cocaine were detected on line and concurrently with the action of cocaine on in vivo detection of DA release. Importantly, the (SC) cocaine response to 5-HT was also habituated; 5-HT release in vlNAcc was reduced by more than 35%. The administration of ibogaine subsequently potentiated the habituated, reduced 5-HT response in vlNAcc seen after (SC) cocaine administration. This is an unexpected finding because ibogaine per se significantly increased 5-HT release in vlNAcc, as shown in Fig. 3 . Interestingly, in the presence of (SC) cocaine, it appears that ibogaine acts at the synapse to further decrease 5-HT when 5-HT is less available a priori.

The effects of cocaine on 5-HT release when administered (SC) vs. (IP) in vlNAcc are different. Whereas (SC) cocaine decreases 5-HT release in vlNAcc of freely moving and behaving rats (7), (IP) cocaine increases 5-HT release in vlNAcc of freely moving and behaving rats (13) . Whereas ibogaine potentiated the decreased 5-HT release induced by (SC) cocaine, ibogaine also appears to potentiate the (IP) cocaine increase in 5-HT release in vlNAcc as well (preliminary data from this laboratory). Thus, ibogaine seems also to act on 5-HT release, dependent on the availability of 5-HT in the synapse. The mechanism, unlike DA though, is bidirectional.

As far as direct receptor subtype for 5-HT is concerned, it is presently unclear which specific 5-HT receptor subtype is involved in the action of ibogaine. Recent behavioral studies suggest the functional involvement of the 5-HT2 receptor and the possible functional involvement of the 5-HT~A receptor in the stimulus properties of ibogaine (49) . However, direct radioligand binding studies, using DPAT for 5-HTIA, 5-HT for 5-HTI~, mesulergine for 5-HTlc, 5-HT for 5-HT~D, ketanserin for 5-HT 2 and GR65630 for 5-HT 3 show that ibogaine did not bind to any of these receptor subtypes (19) . Future studies of ibogaine's interaction with subclassifications of the 5-HT4.5.6 and 7 receptors may clarify the 5-HT receptor binding properties of ibogaine. Studies of ibogaine's interaction with subclassifications of the 5-HT2 receptor are currently underway in this laboratory.

A great deal of discussion has evolved about the possibility of ibogaine exerting a neurophysiological influence through a metabolite. Metabolites of iboga have already been studied; antileukemic activity (37) and antitumoral activity have been reported (38) . Although, the present studies do not directly address the metabolic aspect of ibogaine, we found that ibogaine's effects on cocaine mechanisms were more dramatic in the later hours. Too, the studies by Dzoljic, Glick, and Sershen point to a study of the possible metabolites of ibogaine, as deserving. Along these lines, it is interesting that the dimeric Vinca alkaloid vinblastine, the well-known antineoplastic agent, undergoes metabolic transformation to iboga by the human serum copper oxidase ceruloplasmin, using chlorpromazine as the shuttle oxidant (25) . On the other hand, the dimeric Vinca alkaloid, leurosine, consists of an Iboga substructure which oxidizes to 15-hydroxycatharine (32) . Thus, further study on the active metabolites of ibogaine is importantly underway (44) .

Summarily, the present data, show that ibogaine per se releases 5-HT in vlNAcc, potentiates the 5-HTergic actions of cocaine, and exhibits highly correlative values with both cocaine-induced DA release and psychostimulant behavior. Therefore, the data suggest that ibogaine acts to regulate cocaine through 5-HTergic neuronal activity in the Al0 DA circuit. Critical though to ibogaine's manipulation of cocaine effects on biogenic amines and behavior is that the cocaine response had to be habituated for ibogaine to be effective. A role for the habituated response to cocaine, presumably environmental, then, is emphasized, for ibogaine-cocaine interactions.

The structure of ibogaine

Chemically modified electrode for in vivo monitoring of brain catecholamines

Electrochemical evaluation of stearate modified graphite paste electrodes: Selective detection of dopamine is maintained after exposure to brain tissue

Distinguishing in vitro electrochemical signatures for norepinephrine and dopamine

Characterizing stearate probes in vitro for the electrochemical detection of dopamine and serotonin

State-of-the-Art microelectrodes for in vivo voltammetry

Cocaine-on-line analysis of an accumbens amine neural basis for psychomotor behavior

In vivo voltammetric studies on release mechanisms for cocaine with -/-butyrolactone

Cocaine's colocalized effects on synaptic serotonin and dopamine in ventral tegmentum in a reinforcement paradigm

Distinguishing effects of cocaine (IV) and (SC) on mesoaccumbens dopamine and serotonin release with chloral hydrate anesthesia

In vivo electrochemical studies of gradient effects of (SC) cocaine on dopamine and serotonin release in dorsal striatum of conscious rats

Dopamine and serotonin in rat striatum during in vivo hypoxic-hypoxia

Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat

Ibogaine alters cocaine-induced biogenic amine and psychostimulant dysfunction but not [3H]GBR-12935 binding to the dopamine transporter protein

Inhibitory effects of ibogaine on cocaine self administration in rats

Effect of tabernanthine on the turnover time of brain catecholamines in normal and hypobaric hypoxic rats

Modification of awakesleep equilibrium by tabernanthine and some of its derivatives in the cat

Restoration of sleep in cats pretreated with tabernanthine pchlorophenoxyacetate (SAD 103)

Mechanism of action of ibogaine and harmaline congeners based on radioligand binding studies

Neocortical rhythmic slow activity during wakefulness and paradoxical sleep in rats

A comparative study on the toxicity of ibogaine and serotonin

The identification of ibogaine in biological material

The chemistry of the psychotomimetic substances

Effects of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats

In vitro metabolic transformations of vinblastine: Oxidations catalyzed by human ceruloplasmin

Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice

A psychopharmacological study of some indole alkaloids

Approaches to the characterization of drug effects on locomotor activity in rodents

Interactions of ibogaine with morphine in rats: Drug selfadministration and in vivo microdialysis

Effects of ibogaine on acute signs of morphine withdrawal in rats: Independence from tremor

Effects and after effects of ibogaine on morphine self-administration in rats

Leurosine biotransformations: An unusual ringfission reaction catalyzed by peroxidase

Objective measures in determining the central effectiveness of a new antihypoxidotic SL 76188: Pharmaco-EEG, psychometric and pharmacokinetic analyses in the elderly

Effects of tabernanthine on calcium and catecholamine stimulated contractions of isolated vascular and cardiac muscle

Peripheral cardiovascular effects of tabernanthine tartrate in anaesthetized rats

Environmental determinants of brain architecture and of behavior: Early experience and learning

Cytotoxicity of modified indole alkaloids

Studies on the total synthesis of bisindole alkaloids in the vinblastine-vincristine series

Rapid method for interrupting the cocaine and amphetamine abuse syndrome

Interactions between ibogaine and cocaine in rats: In vivo microdialysis and motor behavior

Interactions between ibogaine, a potential anti-addictive agent and morphine: An in vivo microdialysis study

Interactions of ibogaine, and D-amphetamine: In vivo microdialysis and motor behavior in rats

Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats

HCl) (Enda-buse®): Pharmacokinetic/pharmacodynamic and safety trial

The action of tabernanthine on noradrenaline-stimulated contractions and 45 Ca movements in rat isolated vascular smooth muscle

Evidence for an antagonistic action of tabernanthine on hypoxia-induced changes in brain serotonin levels

Ibogaine induces glial activation in parasagittal zones of the cerebellum

Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline

Stimulus effects of ibogaine in rats trained with yohimbine

A stereotaxic atlas of the rat brain

Immunohistochemical analysis of serotonin, dopamine and GABA in dorsal and ventral striatum

Convergence of serotonin and dopamine in ventrolateral nucleus accumbens: Anatomical and in vivo electrochemical analysis

Cocaine receptors on dopamine transporters are related to self administration of cocaine

Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue

Cocaine discrimination is attenuated by isradipine and CGS 10746B

Cocaine: Discussion on the role of dopamine in the biochemical mechanism of cocaine action

Neuropharmacological studies on ibogaine, an indole alkaloid with central stimulant properties

The plant kingdom and hallucinogens

Ibogaine reduces amphetamine-induced locomotor stimulation in C57

BL/6 By mice but stimulates locomotor activity in rats

Ibogaine antagonizes cocaine-induced locomotor stimulation in mice

Ibogaine fails to reduce naloxoneprecipitated withdrawal in the morphine dependent rat

Structure-activity relationships of intracerebrally injected tremorigenic indole alkaloids

A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: Serotonergic medication of behavioral effects in rats

A note on the connections and development of the nucleus accumbens

Indole alkaloids, an introduction to the enamine chemistry of natural products

Iboga alkaloids. The structure of ibogaine, ibogamine and tabernanthine

Ibogaine neurotoxicity raises new questions in addiction research

The involvement of subtypes of the 5-HT l receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino)-tetralin in the rat

Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence

The effect of alkaloids from tabernanthe iboga H. Bn. on the response of isolated organs to catecholamines and the possible role of calcium exchange

Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: Potential sites for modulation of mesolimbic dopamine neurons

Ultrastructure of serotoninimmunoreactive terminals in the core and shell of the rat nucleus accumbens: Cellular substrates for interactions with catecholamine afferents

Microvoltammetric electrodes

Chlorpromazine and haloperidol-induced changes in some behavioral effects of cocaine and amphetamine

Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: Effects on tremors induced by oxotremorine, harmine and ibogaine, a comparison with prolyl-leucylglycine amide (MIF), anti-parkinsonian drugs and clonazepam

Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids

The cocaine research was supported in part by NIDA Award R01 DA04755 and PSC/CUNY Awards RF 669201. The ibogaine and ibogaine-cocaine research was supported by PSC/CUNY Awards RF 661188 and 664033 and DHHS BRSG PHS Award 2-S07-RR07132-20 to P. A. Broderick.